Hisun Biopharmaceuticals

Hisun Biopharmaceuticals is a prominent Chinese biotechnology company focused on the research, development, and large-scale manufacturing of biologics and biosimilars. Originally the biologics division of Zhejiang Hisun Pharmaceutical, it became an independent entity following a major investment from PAG and subsequently listed on the Shanghai Stock Exchange STAR Market in 2022. The company's portfolio is anchored by several approved biosimilars, including Anteron (adalimumab), which target autoimmune and inflammatory diseases. Hisun Biopharmaceuticals maintains a robust pipeline of innovative monoclonal antibodies and small molecules in oncology and immunology. With advanced GMP-compliant facilities in Taizhou, the company is positioned as a key player in the domestic Chinese biologics market with expanding global aspirations.